Royal Bank of Canada vs Smith & Nephew plc — how do they compare? Royal Bank of Canada trades at $206.91 (market cap $289.01B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Royal Bank of Canada is far larger — about 24.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| RY | SNN | |
|---|---|---|
Market Cap | $289.01B | $11.63B |
Sector | Financials | Health |
52-Week High | $217.87 | $38.53 |
52-Week Low | $143.64 | $27.80 |
Dividend Yield | 2.43% | 2.85% |
Enterprise Value | — | $14.66B |
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $209.00, down 0.76% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $3.07 per share, beating estimates of $2.89, continuing a trend of quarterly beats. Revenue growth accelerated to $66.53 billion in 2025, with net income margin improving to 32.01% and ROE at 17.2%. Recent corporate actions include dividend declarations of $1.76 per share payable in November 2026.
RY demonstrates solid fundamental strength with consistent earnings outperformance and robust profitability metrics. The stock faces valuation concerns with a P/E of 18.23 and P/S of 5.69, while analyst sentiment remains mixed with 43% buy ratings versus 53% hold. Key risks include stretched bank valuations and macroeconomic sensitivity, but the company's diversified business model and record earnings provide stability for long-term investors.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Trailing returns across standard periods
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →